Research Paper Volume 12, Issue 4 pp 3312—3339

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy


Figure 2. Kaplan-Meier plots of high-risk and low-risk subtypes of LUAD in 9 validation cohorts of (A) GSE72094, (B) GSE68465, (C) GSE50081, (D) GSE42127, (E) GSE41271, (F) GSE31210, (G) GSE30219, (H) GSE13213, and (I) GSE11969.